AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly neutralizing antibodies (bNAbs)(1,2). However even the best bNAbs neutralize 10–50% of HIV-1 isolat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Matthew R., Kattenhorn, Lisa M., Kondur, Hema R., von Schaewen, Markus, Dorfman, Tatyana, Chiang, Jessica J., Haworth, Kevin G., Decker, Julie M., Alpert, Michael D., Bailey, Charles C., Neale, Ernest S., Fellinger, Christoph H., Joshi, Vinita R., Fuchs, Sebastian P., Martinez-Navio, Jose M., Quinlan, Brian D., Yao, Annie Y., Mouquet, Hugo, Gorman, Jason, Zhang, Baoshan, Poignard, Pascal, Nussenzweig, Michel C., Burton, Dennis R., Kwong, Peter D., Piatak, Michael, Lifson, Jeffrey D., Gao, Guangping, Desrosiers, Ronald C., Evans, David T., Hahn, Beatrice H., Ploss, Alexander, Cannon, Paula M., Seaman, Michael S., Farzan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352131/
https://www.ncbi.nlm.nih.gov/pubmed/25707797
http://dx.doi.org/10.1038/nature14264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352131/
https://www.ncbi.nlm.nih.gov/pubmed/25707797
http://dx.doi.org/10.1038/nature14264

Ejemplares similares